Canada
· Delayed Price · Currency is CAD Defence Therapeutics Company Description
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases.
The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program.
The company also offers Dendritic Cell (DC) cancer vaccines using Accum; a protein‐based vaccine formulation against COVID and infectious diseases; and a cervical cancer vaccine.
The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020.
The company was incorporated in 2017 and is headquartered in Montreal, Canada.
| Country | Canada |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Sebastien Plouffe |
Contact Details
Address: 7171 Rue Frederick-Banting Montreal, British Columbia H4S1Z9 Canada | |
| Phone | 514 947 2272 |
| Website | defencetherapeutics.com |
Stock Details
| Ticker Symbol | DTC |
| Exchange | Canadian Securities Exchange |
| Share Class | Class A Shares |
| Fiscal Year | July - June |
| Reporting Currency | CAD |
| ISIN Number | CA24463V1013 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sebastien Plouffe | Chief Executive Officer, President and Director |
| Arnab Kumar De A.C.M.A., C.M.A., C.P.A., CGMA, M.B.A. | Chief Financial Officer and Corporate Secretary |
| Dr. Mark Lambermon Ph.D. | Head of Quality and Operations |
| Dr. Maxime Parisotto | Chief Scientific Officer |